Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295999 | 1.00 | CYP2D6 (0.44) | CYP2D6ALDH1A1EPHX2CYP3A4TSHR | |
| SCHEMBL25000116 | 0.92 | CYP2D6 (0.48) | CYP2D6ALDH1A1CYP3A4TSHRMEN1 | |
| SCHEMBL27979606 | 0.86 | GAA (0.45) | CYP2D6ALDH1A1EPHX2CYP3A4TSHR | |
| SCHEMBL11301180 | 0.86 | CYP3A4 (0.53) | CYP2D6ALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL27524659 | 0.83 | CYP2D6 (0.49) | CYP2D6ALDH1A1CYP3A4TSHRMEN1 | |
| SCHEMBL2072649 | 0.82 | ALDH1A1 (0.40) | CYP2D6ALDH1A1CYP3A4TSHRMEN1 | |
| SCHEMBL16589463 | 0.79 | L3MBTL1 (0.41) | ALDH1A1TSHRMEN1KMT2AMAPT | |
| SCHEMBL21908926 | 0.78 | CYP3A4 (0.41) | ALDH1A1CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL28725843 | 0.77 | MAPT (0.47) | CYP2D6MEN1KMT2AKDM4EMAPT | |
| SCHEMBL15924822 | 0.77 | CYP2D6 (0.43) | CYP2D6ALDH1A1CYP3A4TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8759334-B2 | Compounds useful for the treatment of metabolic and inflammatory diseases | GALAPAGOS NV (BE) | 2014-06-24 | — | — | US | disclosed |
| EP-2665704-A1 | AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | Galapagos NV (BE) | 2013-11-27 | — | — | EP | disclosed |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-11-14 | — | — | US | disclosed |
| WO-2012098033-A1 | AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2012-07-26 | — | — | WO | disclosed |
| WO-2008135525-A2 | SUBSTITUTED AZETIDINES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | CYP2D6 1784/4885ALDH1A1 1373/4885EPHX2 2184/4885 |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | CYP2D6 1784/4885ALDH1A1 1373/4885EPHX2 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.